The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +55

Pullback Created an Attractive Entry Point in The Cooper Companies (COO)

AI-generated analysis

πŸ“ˆ Harris Oakmark's Oakmark Global Fund added The Cooper Companies (COO) as a new position in its Q2 2026 investor letter.

πŸ’° The stock closed at $68.51 per share on July 14, 2026, representing a 7.35% one-month return but a 3.95% loss over the past 52 weeks.

🏒 Cooper operates through two main segments: CooperVision, which manufactures contact lenses, and CooperSurgical, focused on women's health products.

πŸ“‰ The company has a market capitalization of $13.36 billion and trades at a meaningful discount to public peers and private market transactions.

πŸ’Ž Oakmark highlights the oligopolistic structure of the contact lens industry as providing significant barriers to entry and recurring revenue streams.

πŸš€ Recent strategic steps include improving free cash flow conversion, reaccelerating growth, and optimizing the product portfolio.

πŸ“Š Cooper has an impressive track record of gaining market share, attributed to its leading position in specialty lenses and unique private-label strategy.

πŸ“‰ Hedge fund interest is waning slightly, with 49 portfolios holding the stock at the end of Q1 2026 compared to 53 in the previous quarter.

πŸ€– The article notes that while Cooper is a value play, some AI stocks may offer higher returns over a shorter timeframe according to the fund's perspective.

πŸ“° Needham recently raised its price target on COO to $101, indicating external analyst confidence in the company's prospects.

Bullish Signals
  • The Oakmark Global Fund initiated a new position in The Cooper Companies, signaling institutional confidence in its long-term value.
  • The stock trades at a meaningful discount relative to public peers, private market transactions, and its own historical trading levels.
  • CooperVision benefits from an oligopolistic market structure with high barriers to entry and historically consistent positive pricing dynamics.
  • The company has demonstrated an impressive track record of gaining contact lens market share through specialty lenses and a unique private-label strategy.
  • Management has taken recent steps to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio.
  • Needham raised its price target on COO to $101, reflecting positive analyst sentiment regarding the company's fundamentals.
Risk Factors
  • The Oakmark Global Fund underperformed its benchmark in Q2 2026, delivering a 7.89% return compared to the MSCI World Index's 13.76% gain.
  • Hedge fund portfolios holding The Cooper Companies decreased from 53 in Q1 2026 to 49 at the end of Q1 2026, indicating some institutional rotation away from the stock.
  • The article suggests that some AI stocks may hold greater promise for delivering higher returns over a shorter timeframe compared to The Cooper Companies.
Full Analysis
Harris Oakmark recently released its second-quarter 2026 investor letter for the Oakmark Global Fund, a non-diversified fund focusing on long-term capital appreciation. The fund delivered a 7.89% return in Q2, lagging the MSCI World Index's 13.76% gain, with energy and industrials driving performance while health care and consumer discretionary detracted. The firm emphasizes evaluating companies based on competitive advantages, cash flow potential, and valuation rather than market predictions. The Oakmark Global Fund highlighted The Cooper Companies (NASDAQ: COO) as a newly added position in its Q2 2026 update. The medical device company, which operates through CooperVision and CooperSurgical segments, closed at $68.51 per share on July 14, 2026. Oakmark views the stock as an attractive entry point following a sharp pullback alongside the broader medical technology sector, noting it trades at a meaningful discount to public peers, private market transactions, and its own trading history. The fund praises Cooper's oligopolistic market structure in contact lenses, which offers significant barriers to entry, recurring revenue streams, and consistent positive pricing dynamics supporting mid-single-digit growth. Oakmark is encouraged by the company's track record of gaining market share through specialty lenses and a unique private-label strategy. Additionally, recent steps to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio have strengthened the investment thesis. Despite being added by Oakmark, The Cooper Companies is not currently on Insider Monkey's list of 40 most popular stocks among hedge funds heading into 2026. Hedge fund holdings decreased slightly from 53 portfolios in Q1 to 49 at the end of Q1 2026. While acknowledging the risk and potential, the article suggests that some AI stocks may offer higher returns over a shorter timeframe compared to Cooper, though it maintains that Cooper represents a solid value play for investors seeking exposure to medical devices.